EUCTR2010-024262-22-DE进行中（未招募）1 期
Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib or interferon alpha maintenance therapy. - Tasigna and Interferon alpha evaluation initiated by the German CML Study Group – the TIGER study
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 720
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of Ph chromosome [t(9;22)(q34;q11)].
- •Ph negative cases or patients with variant translocations who are BCR-ABL positive in multiplex PCR (Cross, et al 1994) are eligible as well.
- •Pretreatment with hydroxyurea for 6 months and imatinib or nilotinib for a duration of up to 6 weeks is permitted.
- •Age = 18 years old (no upper age limit given)
- •Normal serum levels =LLN (lower limit of normal) of potassium, magnesium, total calcium corrected for serum albumin, or corrected to within normal limits with supplements.
- •ASAT and ALAT = 2.5 x ULN (upper limit of normal) or = 5.0 x ULN if considered due to leukemia
- •Alkaline phosphatase = 2.5 x ULN unless considered due to leukemia
- •Total bilirubin = 1.5 x ULN, except known Mb. Gilbert
- •Serum lipase and amylase = 1.5 x ULN
- •Serum creatinine = 2 x ULN
- •Written informed consent prior to any study procedures being performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 245
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 475
排除标准
- •Known impaired cardiac function, including any of the following:
- •- Left ventricular ejection fraction (LVEF) < 45%
- •- Congenital long QT syndrome
- •- History of or presence of clinically significant ventricular or atrial tachyarrhythmias
- •Clinically significant resting bradycardia (< 50 beats per minute)
- •QTc>450 msec on screening ECG. If QTc > 450 ms and electrolytes are not within normal ranges before nilotinib dosing, electrolytes should be corrected and then the patient rescreened for QTc criterion.
- •Myocardial infarction within 12 months prior to starting therapy.
- •Other clinical significant heart disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension)
- •History of acute (i.e., within 1 year of starting study medication) or chronic pancreatitis
- •Acute or chronic viral hepatitis with moderate or severe hepatic impairment (Child-Pugh scores >6), even if controlled.
- •Other concurrent uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol
- •Impaired gastrointestinal function or disease that may alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea, malabsorption syndrome, small bowel resection or gastric by-pass surgery)
- •Concomitant medications with potential QT prolongation (see link for complete list: http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm)
- •Concomitant medications known to be strong inducers or inhibitors of the CYP450 isoenzyme CYP3A4:
- •see link for complete list (http://medicine.iupui.edu/flockhart/table.htm)
- •Patients who have undergone major surgery = 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
- •Patients who are pregnant or breast feeding, or women of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to administration of nilotinib). Post menopausal women must be amenorrheic for at least 12 months in order to be considered of non-childbearing potential. Female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug
- •Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)
- •Active autoimmune disorder, including autoimmune hepatitis
- •Known serious hypersensitivity reactions to peginterferon alfa-2b or interferon alfa-2b or drug excipients
- •Known serious hypersensitivity reactions to nilotinib
- •Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
- •Patients unwilling or unable to comply with the protocol.
研究者
相似试验
进行中（未招募）
1 期
Attempt of treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase: initially with a combination of nilotinib and interferon alpha followed by a nilotinib or interferon alpha maintenance therapychronic phase CMLMedDRA version: 16.0Level: LLTClassification code 10009700Term: CMLSystem Organ Class: 100000004864EUCTR2010-024262-22-CZFriedrich-Schiller-Universität Jena628
进行中（未招募）
不适用
Front-line treatment of Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL) with two tyrosine kinase inhibitors (TKI) (Imatinib and Nilotinib). A phase II exploratory multicentric study in elderly patients and in patients unfit for program of intensive therapy and allogeneic stem cell transplantation - GIMEMA LAL1408EUCTR2009-013271-22-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL`ADULTO
进行中（未招募）
1 期
Optimization of therapy in adult patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma by individualised, targeted and intensified treatmentEUCTR2013-003466-13-DEGoethe University Frankfurt900
进行中（未招募）
1 期
Optimization of treatment for patients with chronic hepatitis C infected with a particular virus type (HCV-genotype 2 or 3): 12 vs. 24 weeks of treatment extension for patients with slow response to therapyEUCTR2008-000706-36-DEHannover Medical School; Competence Network Viral Hepatitis (Hep-Net)150
进行中（未招募）
不适用
Pre-emptive targeted and optimized treatment of critical airway colonization to prevent Ventilator Associated Pneumonia: a randomized controlled studyVentilator Associated PneumoniaMedDRA version: 15.0Level: LLTClassification code 10047263Term: Ventilation pneumonitisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-002774-31-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI